HONG KONG – November 03, 2026 -- WuXi Biologics (2269.HK) won two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), the only pharmaceutical company to do so among 120 entries.

BAD HOMBURG – – November 02, 2026 -- Fresenius has secured exclusive rights to up to 37 biosimilar candidates under a development agreement with WuXi Biologics. The company calls it the largest development agreement announced in the biosimilars industry to date. The deal could lift Fresenius' portfolio from 29 marketed and pipeline molecules today to as many as 66 over the next decade, addressing more than €370 billion in originator list-price-based sales.

Shanghai – October 21, 2026 -- WuXi Biologics (2269.HK) won the Jade Award, the highest distinction at The Asset Corporate Sustainability Leadership Awards 2026, and was the only pharmaceutical company among this year's Jade recipients. The contract research, development and manufacturing organization (CRDMO) also took the Best in Transition (Hong Kong) award.

Basel – October 19, 2026 -- WuXi Biologics will expand annual capacity to approximately 300 IND programs and 20 BLA programs by 2027, as bispecific antibodies and ADCs made up 71% of the 169 projects it added in the first half of 2026. More than two-thirds of those new programs originated in the United States and Europe, the company said at its 3rd annual Basel CRDMO+ Day, held alongside Festival of Biologics Basel 2026, which drew more than 3,000 industry professionals.

Milan – October 09, 2026 -- WuXi Biologics is pitching a European manufacturing footprint of 54,000 L of drug-substance capacity in Dundalk, Ireland, plus a 12,000 L site in Wuppertal, Germany, to biopharma clients at CPHI Milan 2026, as Europe's biologics market is projected to grow from an estimated US$123.75 billion in 2025 to about US$269.65 billion by 2035.

The market is forecast to expand at a CAGR of 8.1% from 2026 to 2035. CPHI Milan 2026 brings together more than 62,000 pharmaceutical professionals and 2,900 exhibitors.

Morristown, N.J. – September 16, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.

Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.